Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1998-03-11
2001-11-27
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S244000, C514S420000, C514S707000
Reexamination Certificate
active
06323218
ABSTRACT:
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY-SPONSORED RESEARCH AND DEVELOPMENT
BACKGROUND OF THE INVENTION
Part of the work performed during the development of this invention utilized U.S. Government Funds under Grant No. R29AG12686 from the National Institutes of Health. The government may have certain rights in this invention.
1. Field of the Invention
This invention is in the field of medicinal chemistry. In particular, the invention is related to compositions for treatment of Alzheimer's disease.
2. Related Art
Polymers of Abeta (A&bgr;), the 4.3 kD, 39-43 amino acid peptide product of the transmembrane protein, amyloid protein precursor (APP), are the main components extracted from the neuritic and vascular amyloid of Alzheimer's disease (AD) brains. A&bgr; deposits are usually most concentrated in regions of high neuronal cell death, and may be present in various morphologies, including amorphous deposits, neurophil plaque amyloid, and amyloid congophilic angiopathy (Masters, C. L., et al.,
EMBO J
. 4:2757 (1985); Masters, C. L. el al.,
Proc. Natl. Acad. Sci. USA
82: 4245 (1985)). Growing evidence suggests that amyloid deposits are intimately associated with the neuronal demise that leads to dementia in the disorder.
The presence of an enrichment of the 42 residue species of A&bgr; in these deposits suggests that this species is more pathogenic. The 42 residue form of A&bgr; (A&bgr;
1-42
), while a minor component of biological fluids, is highly enriched in amyloid, and genetic studies strongly implicate this protein in the etiopathogenesis of AD. Amyloid deposits are decorated with inflammatory response proteins, but biochemical markers of severe oxidative stress such as peroxidation adducts, advanced glycation end-products, and protein cross-linking are seen in proximity to the lesions. To date, the cause of A&bgr; deposits is unknown, although it is believed that preventing these deposits may be a means of treating the disorder.
When polymers of A&bgr; are placed into culture with rat hippocampal neurons, they are neurotoxic (Kuo, Y-M., et al.,
J. Biol. Chem
. 271:4077-81 (1996); Roher, A. E., et al.,
Journal of Biological Chemistry
271:20631-20635 (1996)). The mechanism underlying the formation of these neurotoxic polymeric A&bgr; species remains unresolved. The overexpression of A&bgr; alone cannot sufficiently explain amyloid formation, since the concentration of A&bgr; required for precipitation is not physiologically plausible. That alterations in the neurochemical environment are required for amyloid formation is indicated by its solubility in neural phosphate buffer at concentrations of up to 16 mg/ml (Tomski, S. & Murphy, R. M.,
Archives of Biochemistry and Biophysics
294:630 (1992)), in biological fluids such as cerebrospinal fluid (CSF) (Shoji, M., et al.,
Science
258:126 (1992); Golde, T. E., etal.
Science
, 255(5045):728-730 (1992); Seubert, P., el al.,
Nature
359:325 (1992); Haass, C., et al.,
Nature
359:322 (1992)) and in the plaque-free brains of Down's syndrome patients (Teller, J. K., et al.,
Nature Medicine
2:93-95 (1996)).
Studies into the neurochemical vulnerability of A&bgr; to form amyloid have suggested altered zinc and [H
+
] homeostasis as the most likely explanations for amyloid deposition. A&bgr; is rapidly precipitated under mildly acidic conditions in vitro (pH 3.5-6.5) (Barrow, C. J. & Zagorski, M. G.,
Science
253:179-182 (1991); Fraser, P. E., et al.,
Biophys
. J. 60:1190-1201 (1991); Barrow, C. J., et al.,
J. Mol. Biol
. 225:1075-1093 (1992); Burdick, D.,
J. Biol. Chem
. 267:546-554 (1992); Zagorski, M. G. & Barrow, C. J.,
Biochemistry
31:5621-5631 (1992); Kirshenbaum, K. & Daggett, V.,
Biochemistry
34:7629-7639 (1995); Wood, S. J., et al.,
J. Mol. Biol
. 256:870-877 (1996)). Recently, it has been shown that the presence of certain biometals, in particular redox inactive Zn
2+
and, to a lesser extent, redox active Cu
2+
and Fe
3+
, markedly increases the precipitation of soluble A&bgr; (Bush, A. I., et al.,
J. Biol. Chem
. 268:16109 (1993); Bush, A. I., et al.,
J. Biol. Chem
. 269:12152 (1994); Bush, A. I., et al.,
Science
265:1464 (1994); Bush, A. I., el al.,
Science
268:1921 (1995)). At physiological pH, A&bgr;
1-40
specifically and saturably binds Zn
2+
, manifesting high affinity binding (K
D
=107 nM) with a 1:1 (Zn
2+
:A&bgr;) stoichiometry, and low affinity binding (K
D
=5.2 &mgr;M) with a 2:1 stoichiometry.
The reduction by APP of copper (II) to copper (I) may lead to irreversible A&bgr; aggregation and SDS-resistant polymerization. This reaction may promote an environment that would enhance the production of hydroxyl radicals, which may contribute to oxidative stress in AD (Multhaup, G., et al.,
Science
271:1406-1409 (1996)). A precedence for abnormal Cu metabolism already exists in the neurodegenerative disorders of Wilson's disease, Menkes' syndrome and possibly familial amyotrophic lateral sclerosis (Tanzi, R. E. et al.,
Nature Genetics
5:344 (1993); Bull, P. C., et al.,
Nature Genetics
5:327 (1993); Vulpe, C., et al.,
Nature Genetics
3:7 (1993); Yamaguchi, Y., et al.,
Biochem. Biophys. Res. Commun
. 197:271 (1993); Chelly, J., et al.,
Nature Genetics
3:14 (1993); Wang, D. & Munoz, D. G.,
J. Neuropathol. Exp. Neurol
. 54:548 (1995); Beckman, J. S., et al.,
Nature
364:584 (1993); Hartmann, H. A. & Evenson, M. A.,
Med. Hypotheses
38:75 (1992)).
Although much fundamental pathology, genetic susceptibility and biology associated with AD is becoming clearer, a rational chemical and structural basis for developing effective drugs to prevent or cure the disease remains elusive. While the genetics of the disorder indicates that the metabolism of A&bgr; is intimately associated with the etiopatholgenesis of the disease, drugs for the treatment of AD have so far focused on “cognition enhancers” which do not address the underlying disease processes.
SUMMARY OF THE INVENTION
An aspect of the present invention contemplates a method for treating Alzheimer's disease (AD) in a subject, said method comprising administering to said subject an effective amount of an agent which is capable of inhibiting or otherwise reducing metal-mediated production of free radicals.
The present invention provides a method for treating AD in a subject, said method comprising administering to said subject an effective amount of an agent comprising a metal chelator and/or a metal complexing compound for a time and under conditions sufficient to inhibit or otherwise reduce metal-mediated production of free radicals by A&bgr;.
In one aspect, the free radicals are reactive oxygen species such as O
2
−
or OH•. In another aspect, the free radicals include forms of A&bgr;.
The agent of this aspect of the present invention may contain one or more than one compound such as a metal chelator or metal complexing compound such as but not limited to DTPA, bathocuproine, bathophenanthroline, clioquinol, penicillamine, or derivatives, homologues or analogues thereof. Alternatively, or in addition, the agent may comprise an antioxidant or other molecule capable of interfering with A&bgr; peptide-mediated radical formation.
One aspect of the present invention comprises an agent for use in treating AD in a subject comprising a metal chelator, metal complexing compound and/or a compound capable of inhibiting free radical formation by interaction of A&bgr; peptides and biometals, said agent optionally further comprising one or more pharmaceutically acceptable carriers and/or diluents.
In one aspect, the invention relates to a method of treating amyloidosis in a subject, said method comprising administering to said subject a combination of (a) a metal chelator selected from the group consisting of: bathocuproine, bathophenanthroline, DTPA, EDTA, EGTA, penicillamine, TETA, and TPEN, or hydrophobic derivatives thereof, and (b) clioquinol, for a time and under conditions to bring about said treatment; wherein said combination r
Atwood Craig S.
Bush Ashley I.
Huang Xudong
Tanzi Rudolph E.
Sterne Kessler Goldstein & Fox P.L.L.C.
The General Hospital Corporation
Weddington Kevin E.
LandOfFree
Agents for use in the treatment of Alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agents for use in the treatment of Alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agents for use in the treatment of Alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2572841